Payment overview · 2025
General Payments
$680.76
59 reported records · 8 companies
Healthcare provider profile · identity verified
Sean B Barnes, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ZANESVILLE, OH · NPI 1164620290
Verified facts
What the public records show
CMS Open Payments records show Sean B Barnes, M.D. received $680.76 in general payments during 2025 across 59 reported records.
ABBVIE INC. accounted for 49.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 399 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $339.30 | 49.8% | 29 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $136.79 | 20.1% | 17 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $52.33 | 7.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.96 | 6.8% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $40.56 | 6.0% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $28.44 | 4.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.08 | 2.8% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $18.30 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $680.76 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $191.81 | 17 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $140.46 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $78.71 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $78.71 | 10 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $74.24 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $64.55 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $60.43 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $58.08 | 7 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $52.33 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.96 | 3 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $40.56 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $28.44 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.08 | 2 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $8.36 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $5.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
399 | 65 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 399 | 65 |
| Losartan Potassium | Losartan Potassium | 377 | 98 |
| Atorvastatin Calcium | Atorvastatin Calcium | 364 | 108 |
| Gabapentin | Gabapentin | 324 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 81 |
| Omeprazole | Omeprazole | 285 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 284 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 245 | 59 |
| Mounjaro | Tirzepatide | 213 | 39 |
| Lisinopril | Lisinopril | 198 | 55 |
| Sertraline Hcl | Sertraline Hcl | 186 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 54 |
| Alprazolam | Alprazolam | 157 | 31 |
| Metformin Hcl | Metformin Hcl | 142 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 38 |
| Prednisone | Prednisone | 124 | 81 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 36 |
| Furosemide | Furosemide | 117 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 37 |
| Lamotrigine | Lamotrigine | 106 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 34 |
| Alendronate Sodium | Alendronate Sodium | 94 | 29 |
| Tramadol Hcl | Tramadol Hcl | 88 | 20 |
| Celecoxib | Celecoxib | 87 | 21 |
| Carvedilol | Carvedilol | 83 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 25 |
| Donepezil Hcl | Donepezil Hcl | 78 | 14 |
| Trazodone Hcl | Trazodone Hcl | 69 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 21 |
| Montelukast Sodium | Montelukast Sodium | 62 | 20 |
| Allopurinol | Allopurinol | 57 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 18 |
| Potassium Chloride | Potassium Chloride | 51 | 14 |
| Simvastatin | Simvastatin | 51 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 17 |
| Farxiga | Dapagliflozin Propanediol | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 18 |
| Levofloxacin | Levofloxacin | 49 | 38 |
| Meloxicam | Meloxicam | 44 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 19 |
| Ingrezza | Valbenazine Tosylate | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 11 |
| Spironolactone | Spironolactone | 40 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | 11 |
| Finasteride | Finasteride | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 33 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 11 |
| Lorazepam | Lorazepam | 33 | suppressed |
| Topiramate | Topiramate | 32 | 13 |
| Eliquis | Apixaban | 31 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 20 |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 21 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 24 | 11 |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Praluent Pen | Alirocumab | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Budesonide Dr | Budesonide | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $680.76 · 59 records | ABBVIE INC. | BodyGuardian, CREON, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), EVENITY, INGREZZA, Korlym, LINZESS, OTEZLA, PROLIA, QULIPTA, REPATHA, SYNTHROID, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error